Additionally, levels of pro-survival pathway molecules such as p-MEK1/2, p-AKT, and p-ERK decreased in three of four on-treatment tumor tissue samples compared with pre-treatment tumor tissue. The gene discussed is MAP2K1; the disease is neoplasm.